摘要
目的:探讨丹红注射液对UAP患者血清中MMPs、CK-MB和OX-LDL的影响。方法:将2013年7月-2014年6月在本科室就诊的63例不稳定型心绞痛患者纳入本研究。受试者的年龄在60~82周岁之间,平均(70.4±6.5)岁。将所有纳入的受试者按照性别区域化随机分为2组,分别为对照组(常规的抗冠心病UAP治疗,n=31)和丹红注射液组(在常规治疗方案的基础上每日静脉滴注丹红注射液30 mL,连续14 d,n=32)。采用酶联免疫吸附法测定血清中的MMP-2、MMP-9、CKMB以及OX-LDL水平,并考察心绞痛发作次数和发作持续时间以及心绞痛发作次数与以上血清指标的相关性。结果:本试验纳入的63例患者均无脱落,两组纳入患者的性别[χ2(1)=0.013,P=0.91>0.05]、BMI(P=0.319>0.05)以及年龄(P=0.121>0.05)均未呈现统计学差异。与对照组相比,丹红注射液组患者血清中的MMP-2(P=1.16×10^(-4))、MMP-9(P=4.74×10^(-4))、CK-MB(P=1.31×10^(-3))和OX-LDL(P=2.08×10^(-3))均显著降低,每周心绞痛的发作次数明显减少(P=1.93×10^(-7)),心绞痛的持续时间虽有缩短的趋势,但是无统计学上的差异(P=0.09>0.05)。心绞痛发作次数与以上血清指标显著正性相关。结论:丹红注射液可以显著降低不稳定型心绞痛患者冠状动脉粥样硬化斑块破裂的风险,保护心肌细胞、并在一定程度上缓解冠脉的血管炎性反应。
OBJECTIVE To investigate effects of Danhong injection on MMPs,CK-MB and OX-LDL in serum of UAP patients.METHODS A total of 63 patients with unstable angina pectoris（UAP）treated in the hospital from July 2013 to June2014 were enrolled.Subjects were 60-82（70.4±6.5）years old.Subjects were divided into 2 groups randomly by gender.Subjects in vehicle group received conventional anti UAP therapy regimen（n=31）,and subjects in Danhong injection group received Danhong injection（ivgtt）30 mL daily for 14 days besides of conventional treatment（n=32）.Levels of matrix metalloproteinase-2（MMP-2）,matrix metalloproteinase-9（MMP-9）,creatine kinase-MB（CK-MB）and oxidized low density lipoprotein（OX-LDL）in serum were evaluated by ELISA.Frequency and duration of angina pectoris attack were also assayed.RESULTS No data were lost.No significant difference was observed in gender[χ2（1）=0.013,P=0.910.05],BMI（P=0.3190.05）or age（P=0.1210.05）between two groups.Compared with vehicle group,levels of MMP-2（P=1.16×10^-4）,MMP-9（P=4.74×10^-4）,CK-MB（P=1.31×10^-3）and OX-LDL（P=2.08×10^-3）decreased obviously in Danhong injection group（P〈0.05）.Frequency of angina pectoris attack decreased dramatically（P=1.93×10^-7）.However duration of angina pectoris tended to decrease but showed no statistical significance.Frequency of angina pectoris was positively correlated with above parameters in serum.CONCLUSION Danhong injection can significantly reduce risk of coronary atherosclerotic plaque rupture,protect myocardial cells,and to some extent alleviate coronary vascular inflammation in UAP patients.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2016年第8期650-653,共4页
Chinese Journal of Hospital Pharmacy
基金
承德市科学技术研究与发展计划项目(编号:20122159)
